Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience.

Roerden M, Walz JS, Müller MR, Sökler M, Federmann B, Kanz L, Bethge W, Vogel W.

J Cancer Res Clin Oncol. 2019 Aug 13. doi: 10.1007/s00432-019-02999-9. [Epub ahead of print]

PMID:
31410605
2.

Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report.

Frauenfeld L, Bonzheim I, Wirths S, Steinhilber J, Horger M, Mankel B, Bethge W, Fend F, Federmann B.

Virchows Arch. 2019 Jul 17. doi: 10.1007/s00428-019-02608-7. [Epub ahead of print]

PMID:
31317311
3.

Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression.

Federmann B, Frauenfeld L, Pertsch H, Borgmann V, Steinhilber J, Bonzheim I, Fend F, Quintanilla-Martinez L.

Haematologica. 2019 Jul 11. pii: haematol.2019.219543. doi: 10.3324/haematol.2019.219543. [Epub ahead of print]

4.

Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.

Reinert CP, Federmann B, Hofmann J, Bösmüller H, Wirths S, Fritz J, Horger M.

Eur Radiol. 2019 Jun 24. doi: 10.1007/s00330-019-06291-9. [Epub ahead of print]

PMID:
31236702
5.

Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia.

Schittenhelm MM, Walter B, Tsintari V, Federmann B, Bajrami Saipi M, Akmut F, Illing B, Mau-Holzmann U, Fend F, Lopez CD, Kampa-Schittenhelm KM.

EBioMedicine. 2019 Apr;42:340-351. doi: 10.1016/j.ebiom.2019.03.028. Epub 2019 Apr 2.

6.

Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales.

Federmann B, Mueller MR, Steinhilber J, Horger MS, Fend F.

Ann Hematol. 2018 Oct;97(10):1859-1868. doi: 10.1007/s00277-018-3390-x. Epub 2018 Jun 12.

PMID:
29947976
7.

The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.

Nuebling T, Schumacher CE, Hofmann M, Hagelstein I, Schmiedel BJ, Maurer S, Federmann B, Rothfelder K, Roerden M, Dörfel D, Schneider P, Jung G, Salih HR.

Cancer Immunol Res. 2018 Feb;6(2):209-221. doi: 10.1158/2326-6066.CIR-17-0212. Epub 2018 Jan 10.

8.

Tumor Heterogeneity in Lymphomas: A Different Breed.

Schürch CM, Federmann B, Quintanilla-Martinez L, Fend F.

Pathobiology. 2018;85(1-2):130-145. doi: 10.1159/000475530. Epub 2017 Jul 19. Review.

9.

Generalized palisaded neutrophilic and granulomatous dermatitis-a cutaneous manifestation of chronic myelomonocytic leukemia? A clinical, histopathological, and molecular study of 3 cases.

Federmann B, Bonzheim I, Yazdi AS, Schmidt J, Fend F, Metzler G.

Hum Pathol. 2017 Jun;64:198-206. doi: 10.1016/j.humpath.2017.04.010. Epub 2017 Apr 22.

PMID:
28442268
10.

Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.

Haen SP, Groh C, Schumm M, Backert L, Löffler MW, Federmann B, Faul C, Dörfel D, Vogel W, Handgretinger R, Kanz L, Bethge WA.

Ann Hematol. 2017 May;96(5):817-827. doi: 10.1007/s00277-017-2941-x. Epub 2017 Feb 28.

PMID:
28247058
11.

Cardiac Myeloid Sarcoma: Multimodality Radiologic Imaging Features and Pathologic Correlation.

Dörfel D, Häntschel M, Federmann B, Haen S, Fend F, Müller II, Salih HR, Vogel W, Kanz L, Horger M.

Am J Med. 2016 Aug;129(8):e117-20. doi: 10.1016/j.amjmed.2016.03.028. Epub 2016 Apr 18. No abstract available.

PMID:
27103046
12.

EBV-negative aggressive B-cell lymphomas of donor origin after allogeneic hematopoietic stem cell transplantation: a report of three cases.

Federmann B, Bonzheim I, Schittenhelm J, Quintanilla-Martínez L, Mankel B, Vogel W, Faul C, Bethge W, Fend F.

Leuk Lymphoma. 2016 Nov;57(11):2603-11. doi: 10.3109/10428194.2016.1160088. Epub 2016 Apr 6.

PMID:
27049896
13.

Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.

Schneidawind D, Federmann B, Buechele C, Helwig A, Schmohl J, Vogel W, Faul C, Kanz L, Bethge WA.

Ann Hematol. 2016 Jan;95(1):115-124. doi: 10.1007/s00277-015-2512-y. Epub 2015 Sep 28.

PMID:
26411736
14.

[Differential diagnostic specific skin infiltrates in chronic myelomonocytic leukemia].

Federmann B, Metzler G, Bonzheim I, Fend F.

Pathologe. 2015 Sep;36(5):494-7. doi: 10.1007/s00292-015-0058-3. German.

PMID:
26292933
15.

High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates.

Bonzheim I, Giese S, Deuter C, Süsskind D, Zierhut M, Waizel M, Szurman P, Federmann B, Schmidt J, Quintanilla-Martinez L, Coupland SE, Bartz-Schmidt KU, Fend F.

Blood. 2015 Jul 2;126(1):76-9. doi: 10.1182/blood-2015-01-620518. Epub 2015 Apr 21.

16.

MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.

Schmidt J, Federmann B, Schindler N, Steinhilber J, Bonzheim I, Fend F, Quintanilla-Martinez L.

Br J Haematol. 2015 Jun;169(6):795-803. doi: 10.1111/bjh.13361. Epub 2015 Mar 29.

PMID:
25819228
17.

Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60.

Federmann B, Faul C, Meisner C, Vogel W, Kanz L, Bethge WA.

Bone Marrow Transplant. 2015 Mar;50(3):427-31. doi: 10.1038/bmt.2014.292. Epub 2015 Jan 19.

PMID:
25599161
18.

The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.

Federmann B, Abele M, Rosero Cuesta DS, Vogel W, Boiocchi L, Kanz L, Quintanilla-Martinez L, Orazi A, Bonzheim I, Fend F.

Hum Pathol. 2014 Dec;45(12):2471-9. doi: 10.1016/j.humpath.2014.08.014. Epub 2014 Sep 7.

PMID:
25305095
19.

Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease.

Reinhardt K, Foell D, Vogl T, Mezger M, Wittkowski H, Fend F, Federmann B, Gille C, Feuchtinger T, Lang P, Handgretinger R, Andreas Bethge W, Holzer U.

J Immunol. 2014 Oct 1;193(7):3355-65. doi: 10.4049/jimmunol.1400983. Epub 2014 Sep 3.

20.

Transient abnormal myelopoiesis/acute megakaryoblastic leukemia diagnosed in the placenta of a stillborn Down syndrome fetus with targeted next-generation sequencing.

Federmann B, Fasan A, Kagan KO, Haen S, Fend F.

Leukemia. 2015 Jan;29(1):232-3. doi: 10.1038/leu.2014.258. Epub 2014 Sep 2. No abstract available.

PMID:
25179734
21.

KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.

Michaelis SU, Mezger M, Bornhäuser M, Trenschel R, Stuhler G, Federmann B, Oevermann L, Kanz L, Handgretinger R, Bethge WA.

Ann Hematol. 2014 Sep;93(9):1579-86. doi: 10.1007/s00277-014-2084-2. Epub 2014 Apr 26.

PMID:
24771045
22.

[An unexpected cause of progressive hepatopathy - Case 2/2014].

Federmann B, Lauer UM, Haen S, Kilias A, Artunc F, Riessen R, Fend F, Haap M.

Dtsch Med Wochenschr. 2014 Feb;139(8):378. doi: 10.1055/s-0033-1360047. Epub 2014 Feb 11. German. No abstract available.

23.

Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation.

Stift J, Baba HA, Huber E, Federmann B, Fischer HP, Schmitt-Graeff A, Baurmann H, Bethge W, Schirmacher P, Wrba F, Greinix H, Fend F, Schwerdtfeger R, Shulman HM, Wolff D, Longerich T; Liver Pathology Group of the German-Austrian-Swiss Working Group on GvHD.

Virchows Arch. 2014 Feb;464(2):175-90. doi: 10.1007/s00428-013-1528-8. Epub 2014 Jan 3.

PMID:
24385287
24.

Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia.

Schneidawind D, Federmann B, Faul C, Vogel W, Kanz L, Bethge WA.

Ann Hematol. 2013 Oct;92(10):1389-95. doi: 10.1007/s00277-013-1774-5. Epub 2013 May 8.

PMID:
23652585
25.

Imaging findings and therapy response monitoring in chronic sclerodermatous graft-versus-host disease: preliminary data of a simultaneous PET/MRI approach.

Sauter AW, Schmidt H, Mantlik F, Kolb A, Federmann B, Pfannenberg C, Reimold M, Pichler BJ, Bethge W, Horger MS.

Clin Nucl Med. 2013 Aug;38(8):e309-17. doi: 10.1097/RLU.0b013e3182816559.

PMID:
23455525
26.

[42-year-old patient with portal hypertension - case 6/2012].

Leibold J, Karakaya S, Federmann B, Rockenstiehl M, Heller S, Feucht J, Malek N, Lauer UM.

Dtsch Med Wochenschr. 2012 Jul;137(27):1406. doi: 10.1055/s-0032-1305085. Epub 2012 Jun 28. German.

PMID:
22744870
27.

Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.

Bethge WA, von Harsdorf S, Bornhauser M, Federmann B, Stelljes M, Trenschel R, Baurmann H, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D.

Bone Marrow Transplant. 2012 Nov;47(11):1397-402. doi: 10.1038/bmt.2012.62. Epub 2012 Apr 16.

PMID:
22504934
28.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study.

Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, Stelljes M, Schwerdtfeger R, Christopeit M, Behre G, Faul C, Vogel W, Schumm M, Handgretinger R, Kanz L, Bethge WA.

Haematologica. 2012 Oct;97(10):1523-31. doi: 10.3324/haematol.2011.059378. Epub 2012 Apr 4.

29.

Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts.

Federmann B, Hägele M, Pfeiffer M, Wirths S, Schumm M, Faul C, Vogel W, Handgretinger R, Kanz L, Bethge WA.

Leukemia. 2011 Jan;25(1):121-9. doi: 10.1038/leu.2010.235. Epub 2010 Oct 14.

PMID:
20944677
30.

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.

Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D.

Blood. 2010 Sep 9;116(10):1795-802. doi: 10.1182/blood-2010-02-270538. Epub 2010 Jun 7.

Supplemental Content

Loading ...
Support Center